奇正藏药
(002287)
| 流通市值：149.43亿 | | | 总市值：149.72亿 |
| 流通股本：5.71亿 | | | 总股本：5.72亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,175,055,354.14 | 403,015,309.71 | 2,337,969,652.39 | 1,471,754,788.04 |
| 营业收入 | 1,175,055,354.14 | 403,015,309.71 | 2,337,969,652.39 | 1,471,754,788.04 |
| 二、营业总成本 | 845,134,478.82 | 323,360,068.03 | 1,858,502,859.3 | 1,166,221,882.87 |
| 营业成本 | 209,238,804.18 | 74,456,695.24 | 418,374,983.28 | 270,919,592.45 |
| 税金及附加 | 23,009,851.17 | 5,653,294.77 | 39,469,702.77 | 28,084,570.42 |
| 销售费用 | 465,680,983.38 | 177,814,815.53 | 1,109,493,320.64 | 667,009,311.27 |
| 管理费用 | 87,799,300.32 | 39,629,675.49 | 170,567,074.65 | 116,005,635.93 |
| 研发费用 | 32,134,569.83 | 11,472,526.65 | 66,730,503.64 | 41,773,785.26 |
| 财务费用 | 27,270,969.94 | 14,333,060.35 | 53,867,274.32 | 42,428,987.54 |
| 其中:利息费用 | 29,418,055.95 | 14,870,045.96 | 57,787,374.57 | 45,334,350.84 |
| 其中:利息收入 | 3,190,765.97 | 1,306,883.5 | 4,185,499.95 | 3,123,839.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 43,330,873.55 | 18,669,206.06 | 105,137,133.35 | 68,211,971.04 |
| 加:投资收益 | -3,930,453.82 | -3,334,451.19 | -4,821,968.32 | 10,696,306.85 |
| 资产处置收益 | 909,309.6 | - | - | - |
| 资产减值损失(新) | 766,877.8 | 879,006.86 | -1,179,197.47 | -242,077.45 |
| 信用减值损失(新) | -18,839.94 | -634,789.61 | 79,678.13 | -266,855.2 |
| 其他收益 | 48,389,216.18 | 3,535,084.98 | 78,342,570.21 | 66,637,637.76 |
| 四、营业利润 | 419,367,858.69 | 98,769,298.78 | 657,025,008.99 | 450,569,888.17 |
| 加:营业外收入 | 42,292.49 | 0.63 | 359,488.24 | 302,881.2 |
| 减:营业外支出 | 16,836,062.03 | 9,741,075.79 | 11,140,310.11 | 9,435,686.52 |
| 五、利润总额 | 402,574,089.15 | 89,028,223.62 | 646,244,187.12 | 441,437,082.85 |
| 减:所得税费用 | 43,121,514.86 | 13,933,703.68 | 64,874,541.4 | 47,068,703.71 |
| 六、净利润 | 359,452,574.29 | 75,094,519.94 | 581,369,645.72 | 394,368,379.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 359,452,574.29 | 75,094,519.94 | 581,369,645.72 | 394,368,379.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 358,394,175.54 | 75,679,793.49 | 582,281,116.79 | 393,375,922.95 |
| 少数股东损益 | 1,058,398.75 | -585,273.55 | -911,471.07 | 992,456.19 |
| 扣除非经常损益后的净利润 | 289,472,475.66 | 65,183,489.42 | 425,808,626.27 | 270,527,162.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.68 | 0.14 | 1.1 | 0.74 |
| (二)稀释每股收益 | 0.68 | 0.14 | 1.1 | 0.74 |
| 八、其他综合收益 | -160,905.25 | -54,508.06 | 561,713.43 | -402,847.11 |
| 归属于母公司股东的其他综合收益 | -160,905.25 | -54,508.06 | 561,713.43 | -402,847.11 |
| 九、综合收益总额 | 359,291,669.04 | 75,040,011.88 | 581,931,359.15 | 393,965,532.03 |
| 归属于母公司股东的综合收益总额 | 358,233,270.29 | 75,625,285.43 | 582,842,830.22 | 392,973,075.84 |
| 归属于少数股东的综合收益总额 | 1,058,398.75 | -585,273.55 | -911,471.07 | 992,456.19 |
| 公告日期 | 2025-08-23 | 2025-04-25 | 2025-04-25 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |